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Background. The diagnosis of primary central nervous system lymphoma (PCNSL) can be challenging. PCNSL lesions are frequently
located deep within the brain, and performing a cerebral biopsy is not always feasible. The aim of this study was to investigate the
diagnostic value of CSF neopterin, a marker of neuroinflammation, in immunocompetent patients with suspected PCNSL.
Methods. We retrospectively reviewed the characteristics of 124 patients with brain tumor (n¼ 82) or an inflammatory CNS dis-
order (n¼ 42) in whom CSF neopterin levels were assessed. Twenty-eight patients had PCNSL, 54 patients had another type of
brain tumor (glioma n¼ 36, metastasis n¼ 13, other n¼ 5), and 13 patients had a pseudotumoral inflammatory brain lesion.
Results. CSF neopterin levels were significantly higher in the patients with PCNSL than in those with other brain tumors (41.8 vs
5.1 nmol/L, P, .001), those with pseudotumoral inflammatory brain lesions (41.8 vs 4.3 nmol/L, P, .001), and those with non-
tumefactive inflammatory CNS disorders (41.8 vs 3.8 nmol/L, P, .001). In the 95 patients with space-occupying brain lesions, at a
cutoff of 10 nmol/L, the sensitivity of this approach was 96% and the specificity was 93% for the diagnosis of PCNSL. The positive
and negative predictive values were 84% and 98%, respectively.
Conclusion. Assessing CSF neopterin levels in patients with a suspected brain tumor might be helpful for the positive and differ-
ential diagnosis of PCNSL. A prospective study is warranted to confirm these results.
Keywords: biomarker, cerebrospinal fluid, neopterin, primary central nervous system lymphoma, space-occupying brain lesion.
Primary central nervous system lymphomas (PCNSLs) are extra-
nodal non-Hodgkin lymphomas affecting the brain, the lepto-
meninges, the spinal cord, and the eye1 in the absence of
systemic lymphoma at the time of diagnosis. These lympho-
mas account for 3% to 5% of primary brain tumors. Diffuse
large B-cell lymphoma (DLBCL) is the most common histopath-
ological PCNSL subtype. PCNSLs are aggressive tumors, and
prompt diagnosis is needed to rapidly initiate appropriate
treatment.
PCNSL MRI characteristics are frequently suggestive of
the diagnosis, showing unique or multiple periventricular,
homogeneously enhancing lesions. In addition, magnetic reso-
nance spectroscopy and perfusion MRI can show suspicious ab-
normalities, such as low regional cerebral blood volume ratios
and very high lipid resonances.2 Yet, MRI characteristics are not
specific, and neuropathological examination is mandatory to
establish the diagnosis. In 10%–30% of cases, lymphoma
cells can be identified in the cerebrospinal fluid (CSF) or in a vit-
reous body biopsy (if a vitreoretinal lymphoma is diagnosed on
slit-lamp examination). However, in the majority of cases, a ce-
rebral biopsy needs to be performed. Nevertheless, performing
a cerebral biopsy can be technically challenging and potentially
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dangerous as PCNSL lesions are frequently located deep within
the brain and can involve all CNS regions, including the brain-
stem. Therefore, biomarkers that would allow the diagnosis of
PCNSL when histological examination is not feasible would be
very helpful.
Neopterin is a nonspecific marker of the type 1 T-helper cell–
related cellular immune response. Its concentration in different
biological fluids such as serum, urine, and CSF has been sug-
gested to be a marker of disease activity in a wide range of in-
fectious and inflammatory diseases. Elevated neopterin levels
in the CSF have been reported in CNS infectious diseases (such
as HIV,3 human T-cell lymphotropic virus type 1–associated
spastic paraparesis,4 and Lyme neuroborreliosis5) and CNS in-
flammatory disorders (inconsistently elevated in multiple scle-
rosis6,7 and high in neurosarcoidosis and neuro-Behc¸et8).
Moderately increased levels have also been reported in ad-
vanced Parkinson disease9 and traumatic brain injuries.10 In
our center, CSF neopterin levels are routinely assessed in pa-
tients suspicious for Creutzfeldt-Jakob disease (CJD) to allow
for the differential diagnosis of inflammatory or infectious neu-
rological conditions. Over the years, we have observed the
cases of several patients suspicious for CJD who yet had elevat-
ed CSF neopterin levels and in whom the final diagnosis was
PCNSL.11,12 These observations prompted us to study the diag-
nostic value of CSF neopterin levels in patients with space-
occupying brain lesions.
Materials and Methods
Patients
Between December 2007 and June 2014, we retrospectively
identified patients from our department with brain tumor or
who were suspicious for brain tumor or with an inflammatory
CNS disorder in whom neopterin levels were assessed in the
CSF. In patients with a space-occupying brain lesion, CSF anal-
ysis was generally performed to identify potential leptomenin-
geal dissemination (at diagnosis or at recurrence) or because of
the suspicion of a tumefactive, nonneoplastic neurological dis-
order. The list of patients with available CSF neopterin levels
was obtained from the records of the neurochemistry depart-
ment and matched with the records of the neuro-oncology
department. A definite neuropathological diagnosis was avail-
able for all patients with a brain tumor.
The medical and radiological files of all patients were re-
viewed. This study has been approved by our institutional eth-
ical committee on human experimentation.
CSF Neopterin Analysis
After collection, the CSF was immediately transported to the
laboratory to be centrifuged at 2000 g at 128+38C for
10 min, after which supernatants were frozen at 2808C until
analysis. The maximum delay between CSF sampling and su-
pernatant freezing was 2 h. The maximum delay between
freezing and analysis was 15 days. CSF neopterin levels were
obtained as previously reported5 using high-performance liquid
chromatography coupled with fluorimetric detection (all tests
were supervised by A.P.-L.). Using pools of CSF samples pre-
pared each year as an internal quality control, the ranges of
yearly interassay coefficients and variability during the period
of patient inclusion were 5.9% and 7% at 7.5 and 1.8 nmol/L
of CSF neopterin, respectively. The upper normal reference
value was previously determined to be 5 nmol/L (upper limit
of the 99% confidence interval).13
Statistical Analysis
Differences between the groups of patients were analyzed
using the Mann–Whitney U-test and the Kruskal–Wallis test,
and P, .05 was considered to be statistically significant. The di-
agnostic accuracy of CSF neopterin levels was assessed using
receiver operating characteristic (ROC) curve analysis. Correla-
tions were assessed using Spearman’s rank test. All statistical
analysis and graphs were performed using SPSS, version 21.0
(IBM).
Results
Patient Characteristics
We identified 82 patients with brain tumors, 13 patients with
pseudotumoral inflammatory brain lesions, and 29 patients
with nontumefactive inflammatory CNS disorders in whom
CSF neopterin levels were assessed (Table 1). Twenty-eight pa-
tients had PCNSL (all were immunocompetent) and 54 patients
had another type of brain tumor.
The histology of PCNSL cases was DLBCL in 24 patients, T-cell
lymphoma in 1 patient, and unclassified lymphoma in 3 pa-
tients. Diagnosis was established using a cerebral biopsy in 26
patients and CSF cytology in 2 patients. The median number of
lesions was 2 (data available for 23 patients, range: 1–6) ac-
cording to MRI analysis. The posterior fossa was involved in
13 of 23 cases (56%), and the mean cumulative lesion volume
(sum of all discrete lesion volumes) was 3.7 cm3 (range: 0.53–
17.2 cm3). None of the patients had received steroids at the
time of CSF analysis.
Among the 54 patients with other brain tumor types, 16 pa-
tients had a newly diagnosed glioma (glioblastoma n¼ 11, an-
aplastic glioma n¼ 3, brainstem glioma n¼ 1, and low-grade
glioma n¼ 1), 20 patients had a recurrent glioma (glioblasto-
ma n¼ 15, anaplastic glioma n¼ 5), 13 patients had brain me-
tastasis (from breast cancer n¼ 5, lung cancer n¼ 5, head and
neck cancer n¼ 1, and unknown origin n¼ 2), and 5 patients
had another type of intracranial tumor (hemangioblastoma
n¼ 1, germinoma n¼ 1, anaplastic meningioma n¼ 1, medul-
loblastoma n¼ 1, and pinealoblastoma n¼ 1). Sixteen patients
had received steroids at the time of CSF analysis.
Among the 13 patients with pseudotumoral inflammatory
brain lesions, 8 patients had demyelinating disease (multiple
sclerosis n¼ 5, neuromyelitis optica n¼ 1, acute disseminated
encephalomyelitis [ADEM] n¼ 1, progressive multifocal leu-
koencephalopathy n¼ 1), 2 patients had a neurosarcoidosis,
2 patients had dysimmune encephalitis (anti– N-methyl-D-
aspartate receptor [NMDAR] encephalitis n¼ 1, and anti–
leucine-rich glioma inactivated 1 encephalitis n¼ 1), and
1 patient had cerebral amyloid angiopathy–related inflamma-
tion. In 5 patients (3 patients with demyelinating disease and
2 patients with dysimmune encephalitis) the diagnosis was
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histologically proven; in the other patients it was based on clin-
ical and biological criteria.
The group of patients with nontumefactive inflammatory
CNS disorders consisted of 10 patients with a paraneoplastic
neurological syndrome associated with or without onconeural
antibodies (anti-Hu n¼ 4, anti-Yo n¼ 2, anti–gamma-amino-
butyric acidB receptor n¼ 1, no antibodies n¼ 3), 14 patients
with a dysimmune encephalitis (anti-NMDAR n¼ 7, anti–
glutamic acid decarboxylase n¼ 4, no antibodies n¼ 3), and
5 patients with demyelinating disease (multiple sclerosis n¼
4, ADEM n¼ 1).
The CSF cell count and CSF protein level were higher in the
patients with PCNSL than in the other groups of patients
(P, .01; Table 1).
Neopterin CSF Levels Are Higher in PCNSL Patients Than
in Patients With Other Types of Brain Tumors
As illustrated in Fig. 1, the median CSF neopterin levels were sig-
nificantly higher in the patients with PCNSL than in the patients
with other types of brain tumors (41.8 vs 5.1 nmol/L, P, .001),
the 13 patients with pseudotumoral inflammatory brain lesions
(41.8 vs 4.3 nmol/L, P, .001), and the 29 patients with nontu-
mefactive inflammatory CNS disorders (41.8 vs 3.8 nmol/L,
P, .001). In the whole series, regardless of the diagnosis, CSF
neopterin levels were positively correlated with CSF cell count
(rho¼ 0.57, P, .01) and with CSF protein levels (rho¼ 0.49,
P, .01). Yet, in the PCNSL patient group, or in the other pa-
tients’ groups, no significant correlation between CSF neopterin
levels and clinical, CSF, imaging, or histological characteristics
could be identified. None of the PCNSL patients exhibited a nor-
mal CSF neopterin value (,5 nmol/L), whereas 52% (28/54) of
the patients with another type of brain tumor exhibited normal
values (P, .001). Two patients with positive CSF cytology had CSF
neopterin levels within the higher range (100 and 134 nmol/L,
one patient had a T-cell lymphoma). In the non-PCNSL tumor
patients, a CSF neopterin level .10 nmol/L was observed in
only 4 patients (10.7, 10.9, 13.2, and 16.9 nmol/L). Three of
these patients had a glioblastoma without particular charac-
teristics compared with the other glioblastoma patients in the
series; the fourth patient had a pinealoblastoma. Within the
subgroups of non-PCNSL tumors, no significant difference was
observed regarding CSF neopterin levels. CSF neopterin levels
were similar in patients who had and had not received steroids
at the time of CSF analysis and in newly diagnosed and recur-
rent gliomas. Among patients with inflammatory CNS disor-
ders, a CSF neopterin level .10 nmol/L was observed in 3
patients with anti-NMDAR encephalitis, in 1 patient with
ADEM, and in 1 patient with anti-Yo cerebellitis.
In the 95 patients with space-occupying brain lesions (82
patients with brain tumors and 13 patients with tumefactive in-
flammatory brain lesions), ROC curve analysis demonstrated
that with a cutoff value of 10 nmol/L, CSF neopterin had a sen-
sitivity of 96%, a specificity of 93%, a positive predictive value of
84%, and a negative predictive value of 98% for the diagnosis
of PCNSL (Fig. 2). In the whole series of 124 patients, at a cutoff
value of 10 nmol/L, CSF neopterin had a sensitivity of 96%, a
specificity of 92%, a positive predictive value of 77%, and a neg-
ative predictive value of 99% for the diagnosis of PCNSL.
Table 1. Demographic and patient CSF characteristics
PCNSL, n¼ 28 Other Brain Tumor
Types, n¼ 54
Pseudotumoral
Inflammatory
Lesions, n¼ 13
Pa Nontumefactive
Inflammatory CNS
Disorders, n¼ 29
Pb
Demographics
Female, n (%) 12 (43) 23 (43) 5 (38) ns 17 (59) ns
Age, y, avg (range) 69 (29–84) 62 (21–84) 55 (19–79) .015 51 (18–78) ,.001
CSF characteristics
Cell count, n, median (range) 11.5 (1–2300) 3 (1–55) 2.0 (1–18) ,.001 1 (1–12) ,.001
Protein, g/L, median (range) 0.93 (0.40–8.5) 0.57 (0.23–11.48) 0.51 (0.23–1.38) .001 0.35 (0.20–0.65) ,.001
Glucose, mmol/L, median (range) 3.45 (1.60–7.15) 3.45 (0.60–7.60) 3.50 (2.5–6.2) ns 3.6 (2.9–4.7) ns
Neopterin, nmol/L, median (range) 41.8 (7.70–135.00) 5.1 (1.90–16.90) 4.3 (1.9–29.2) ,.001 3.8 (1.7–26.5) ,.001
Abbreviation: ns, not significant.
aP-value for PCNSL vs tumoral and pseudotumoral groups.
bP-value for PCNSL vs control group.
Fig. 1. Box plot representation of CSF neopterin levels in PCNSL patients
versus other subgroups. Difference between CSF neopterin levels in PCNSL
versus different subgroups was statistically significant (asterisk bar, P ,
0.001). No significant difference was observed within subgroups. PCNSL:
primary central nervous system lymphoma. GBM: glioblastoma,
GLIOMA: other gliomas, OTHER: other brain tumors, PSEUDO-TUM:
pseudotumoral inflammatory lesions, CONT: nontumefactive
inflammatory CNS disorders. Black dots indicate outliers.
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Discussion
To our knowledge, this is the first study showing that CSF neo-
pterin might be an interesting diagnostic biomarker for PCNSL in
patients with a suspected brain tumor. Neopterin is a pyrazino-
pyrimidine compound that is biosynthesized from guanosine
triphosphate by cells and produced mostly by monocytes and
activated macrophages during interferon-gamma stimulation.
Neopterin is a sensitive marker of cellular immunity activation
and has been shown to induce the expression of several
pro-inflammatory cytokines and other mediators.14 – 16 CSF
neopterin levels have been shown to be elevated in a wide
range of infectious and inflammatory CNS disorders but not
in PCNSL until now. High neopterin levels have been reported
in the serum and urine of patients with systemic hematologic
malignancies.17 – 20 Serum and urinary neopterin levels are
elevated in 90% of patients with hematologic cancers17,18
(lymphomas and leukemias21), and elevated CSF neopterin lev-
els have been reported in children with meningeal relapse of a
systemic hematologic malignancy. Our results are consistent
with these reports and suggest a strong association between
neopterin levels and hematologic malignancies. Whether neo-
pterin in PCNSL is secreted by accompanying inflammatory
cells, tumor cells, or both is unknown. PCNSL is usually charac-
terized by a high degree of microglial infiltration,22 which might
be explained by the secretion of high levels of monocyte
chemoattractants by tumor cells.23 Yet, in certain circumstanc-
es, B cells have also been shown to produce neopterin, and
therefore neopterin could also be secreted by PCNSL tumor
cells.24,25
As CSF neopterin is a nonspecific marker of CNS inflamma-
tion, its diagnostic value can be interpreted only within a
given clinical and radiological context. As shown in the present
study, high CSF neopterin levels can be observed in some
patients with demyelinating disease or with dysimmune en-
cephalitis. Yet, our study suggests that assessing CSF neopterin
levels in patients with a suspected brain tumor could help dif-
ferentiate PCNSL from other types of brain neoplasms. The CSF
neopterin levels were also higher in PCNSL than in the group of
pseudotumoral inflammatory brain lesions; however, the sam-
ple size of this group was too limited to conclude on the diag-
nostic value of neopterin in this setting. In the future it will be
important to determine the diagnostic value of CSF neopterin in
a larger number of patients with pseudotumoral inflammatory
brain lesions (especially in patients with demyelinating disease,
neurosarcoidosis, or neuro-Behc¸et) as well as in patients with
pseudotumoral infectious lesions. It remains to be determined
whether CSF neopterin might be of diagnostic value when
PCNSL does not present as a brain tumor—for example, in
cases presenting as leukoencephalopathy or as isolated lepto-
meningeal involvement.
Several potential CSF diagnostic biomarkers for PCNSL have
been previously reported. CSF levels of soluble cluster of dif-
ferentiation (sCD)27,26 b2-microglobulin,27 anti – thrombin
III,28 free light chain immunoglobulins,29 a specific set
of microRNAs,30 interleukin (IL)-10,31 IL-6,31 sIL2-R,31 and
CXCL1332 have been shown to be elevated in PCNSL. Yet
only CSF levels of IL-10, IL-6, CXCL13, b2-microglobulin, and
sCD27 seem to be higher in PCNSL patients than in patients
with other types of brain tumors (for the other biomarkers, ei-
ther no comparison with other tumor types was performed or
the sample size was too small to allow for robust conclu-
sions). As shown in Table 2, the 96% sensitivity and 93% spe-
cificity of CSF neopterin in our series compare favorably with
the reported diagnostic values of these biomarkers. IL-10 and
CXCL13 seem the most promising biomarkers. IL-10 is impli-
cated in B-cell growth and differentiation, and a recent study
has shown that IL-10 might also be of prognostic value in
PCNSL.31 CXCL13 is a CXC chemokine ligand responsible for
B-cell migration. Elevation of both CXCL13 and IL-10 has
been shown to be highly specific for PCNSL diagnosis.32 In
the future, it might be interesting to combine the analysis
of CSF neopterin levels with one or more of these CSF bio-
markers.31 Coupling the diagnostic value of CSF neopterin
analysis with the diagnostic value of advanced MRI tech-
niques, such as perfusion MRI and MRI spectroscopy, could
be another promising strategy. As for all CSF biomarkers,
one limitation of CSF neopterin analysis is that it cannot be
performed in patients with large tumors and an important
mass effect. However, performing a cerebral biopsy is usually
not a problem in these patients. To circumvent this problem,
neopterin could be assessed in the serum. However, neo-
pterin serum levels are more complicated to interpret than
CSF levels, since high serum levels can be observed in system-
ic infections and in kidney disease in which the serum levels
follow those of creatinine (which is not the case for CSF lev-
els). This is the reason why in our laboratory, neopterin levels
were assessed in the CSF but not in the serum until now. An-
other important question is whether serial CSF neopterin val-
ues would aid in monitoring therapy and in diagnosing
recurrence, as demonstrated for IL-10.31
In conclusion, the present study suggests that CSF neopterin
might be an interesting diagnostic biomarker in patients with
suspected PCNSL. High CSF neopterin levels could allow the
Fig. 2. CSF neopterin level values receiver-operator characteristic (ROC)
curve in patients with space occupying brain lesions. Area under the
curve is 0.982 (confidence interval: 0.961–1). For a cut-off value of
10 nmol/L, the sensitivity was 96% and the specificity 93%.
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Table 2. Summary of previously reported potential CSF biomarkers for PCNSL diagnosis
CSF Biomarker Biomarker Potential Role in PCNSL Sensitivity Specificity Groups Technique Reference
sCD27 Secreted by malignant B cells and
activated lymphocytes
100% 82% 4 PCNSL, 45 SCNSL,
3 BT, 21 MET, 165 O (165 CNS staging)
ELISA Kersten et al, 199626
b2-microglobulin Component of the MHC-1; related to
lymphocytes turnover
68–100% Moderate 6 PCNSL, 4 SCNSL,
12 BT, 7 MET, 79 O (mostly
neuro-inflammatory disorders)
ELFA Caudie et al, 200527
Anti–thrombin
III
Modulation of tumor angiogenesis 75% 98% 20 PCNSL, 3 SCNSL,
3 BT, 8 MET, 77 O (various)
ELISA Roy et al, 200828
FLC Excess secretion of kappa and lambda
free immunoglobulin light chains
Moderate High 17 PCNSL, 4 SCNSL,
5 BT, 0 MET, 9 O (various)
FLCA Schroers et al,
201029
miRNA Deregulated expression of those
posttranscriptional gene regulators
96% 97% 39 PCNSL,
0 BT, 0 MET, 30 O (various)
miRNA extraction kit Baraniskin et al,
201130
IL-10 Cytokine implicated in B-cell growth
and differentiation
71% 100% 31 PCNSL,
49 BT, 8 MET, 2 O (MS)
ELISA Sasayama et al,
201231
IL-6 Cytokine involved in lymphoid growth
and differentiation
77% 63% CLEIA
sIL2-R Marker of T-cell activation 57% 81% ELISA
CXCL13 (+IL-10) CXC chemokine ligand responsible for
B-cell migration
71% (50%) 91% (99.3%) 60 PCNSL, 23 SCNSL,
8 BT, 12 MET, 117 O (71
neuro-inflammatory disorders and 46
CNS staging)
ELISA Rubenstein et al,
201332
Neopterin Marker of Th1-related cellular immune
response activation
96% 93% 28 PCNSL,
41 BT, 13 MET, 13 PSD-T, 29 NON-T
HPLC/FD Present study
Abbreviations: BT, brain tumors; CLEIA, chemiluminescent enzyme immunoassay; CNS staging, CSF analysis performed for the staging of systemic lymphomas or leukemias; ELFA,
enzyme-linked fluorescent assay; ELISA, enzyme-linked immunosorbent assay; FLC, free light chain immunoglobulin; FLCA, free light chain assay; HPLC/FD, high-performance liquid
chromatography coupled with fluorimetric detection; MET, metastasis; miRNA, microRNA; MHC, major histocompatibility complex; MS, multiple sclerosis; n.a., not available, NON-T,
nontumefactive inflammatory CNS disorders; O, other nontumoral neurological disorders; PSD-T, pseudotumoral inflammatory brain lesions; SCNSL, secondary central nervous
system lymphomas; Th1, type 1 T-helper cell.
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diagnosis of PCNSL in patients for whom histological examina-
tion is not feasible or is dangerous. In contrast, low CSF neo-
pterin levels could circumvent the need for a cerebral biopsy
in patients for whom histological examination is performed
with only the aim of ruling out a PCNSL (Fig. 3). A prospective
study is warranted to confirm these results.
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